Endoluminal Spasmolysis
PreclinicalSmall molecule
Endoluminal Spasmolysis is one of 14 small molecule programs targeting Cerebral Infarction. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Cerebral Infarction
#DrugCompanyPhaseTrials
1Radicava
ShionogiApproved
Plavix
SanofiApproved
Lorelco
SanofiApproved
Prevacid
TakedaApproved
Nimotop
AAzurity Pharmaceuticals
Approved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Actos
TakedaPreclinical
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Yangxue Qingnao Pill
PPeking University Third Hospital
Preclinical
Actilyse
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Endoluminal Spasmolysis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRegion Stockholm